Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors

(2019) Gaurav Nayyar et al.   Frontiers in Oncology

NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors

(2019) HA-RAM PARK et al.   CYTOTHERAPY

Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients

(2019) Shin Hye Yoo et al.   Scientific Reports

Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities

(2019) Weilei Hu et al.   Frontiers in Immunology

Drug response to PD-1/PD-L1 blockade: based on biomarkers

(2018) Qi Chen et al.   OncoTargets and Therapy

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

(2018) Estefanía Paula Juliá et al.   Frontiers in Immunology

Termination of the Activating NK Cell Immunological Synapse Is an Active and Regulated Process

(2017) Petra Netter et al.   JOURNAL OF IMMUNOLOGY

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

(2015) Garnet Suck et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

(2015) Wei Wang   Frontiers in Immunology

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Specific growth inhibition of ErbB2‑expressing human breast cancer cells by genetically modified NK‑92 cells

(2014) Hui Liu et al.   ONCOLOGY REPORTS

Classification of human natural killer cells based on migration behavior and cytotoxic response

(2013) B. Vanherberghen et al.   BLOOD

LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity

(2013) K. Krzewski et al.   BLOOD

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan

(2009) Frédéric Bibeau et al.   JOURNAL OF CLINICAL ONCOLOGY

Relationship between CD107a expression and cytotoxic activity

(2008) Esin Aktas et al.   CELLULAR IMMUNOLOGY

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY